CMS administrator defends Medicaid block grants policy

The Trump administration recently released its policy to allow states to opt into Medicaid block granting, a move that fundamentally would shift financing of the federal program. The policy brought swift backlash from the industry, with groups voicing concerns that caps on Medicaid payments will cut spending on needed services and harm patients.

CMS Administrator Seema Verma has since penned an op-ed in the Washington Post defending the policy, dubbed Healthy Adult Opportunity. According to Verma, block grants give states “a historic level of flexibility” to design programs for their beneficiaries.

Verma also vehemently defended that the policy does not lead to Medicaid cuts, calling talking points to that effect as having “a dubious relationship with reality.”

“Nothing could be further from the truth,” she wrote.

“Let me be clear: Fearmongering notwithstanding, HAO does not cut Medicaid funding,” Verma continued. “This optional demonstration continues federal funding to states based on their historical spending with a reasonable growth rate.”

States already can opt to have some of the federal funding for Medicaid under a fixed budget through a section 115 waiver or the Children’s Health Insurance Program (CHIP). The HAO program also allows for adjustments in some circumstances.

Verma also slammed “misinformation” about the new policy and swatted away legal threats.

However, Verma also outlined that the program will help states “prioritize these finite dollars” for the most vulnerable patients. She also underscored the HAO is options and only available to a limited Medicaid population of working-age adults who are not eligible for the federal program of a disability, about 15 million people.

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.